First von Willebrand Disease Patient Dosed with Investigational Sub-Q Therapy

Hemab Therapeutics has begun dosing in their phase 1/2 clinical trial of HMB-002, a subcutaneous prophylactic therapy designed for all types of von Willebrand disease. This investigational treatment uses a monovalent antibody to increase both von Willebrand factor and factor VIII levels. The Velora Pioneer trial, now enrolling participants, will evaluate safety, tolerability, and efficacy, potentially offering a new preventative approach for the most common inherited bleeding disorder.